SABS

SAB BiotherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

20%

Probability

Target price

$9.38

+169.5% vs current

Most likely

Base case

50%

Probability

Target price

$3.75

+7.8% vs current

B-

Bear case

30%

Probability

Target price

$2.25

-35.3% vs current

AI sentiment snapshot

Latest data as of 2026-05-09

AI commentary

Tone stays cautious. As of May 9, 2026, the verified earnings-related company source available in this repair pass was the company IR listing and May 5 notice for Q1 2026 results on May 12, 2026, so there is no confirmed earnings surprise, guidance revision, analyst target change, or true post-print market-reaction evidence yet [#PR-2026-05-05]. The current setup is therefore a monitoring view, not a confirmed post-earnings rerating call. Primary-source support is stronger around the March operating update and the April manufacturing 8-K than around any completed May earnings event [#PR-2026-03-09] [#8-K-2026-05-04]. Social context was not available in the packet, so it does not change confidence.

RankAlpha Sentiment Codex - 2026-05-09

Open post-earnings memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-05-12eventQ1 2026 results and webcast are scheduled for May 12, not yet releasedHigh impact

Company IR listed SAB BIO's Q1 2026 earnings call for May 12, 2026 at 8:30 AM EDT and a May 5, 2026 company notice for first-quarter 2026 financial results, so this run should be treated as a pre-release monitoring check rather than a completed post-print readthrough [#PR-2026-05-05].

2026-05-15catalystNear-term cash and burn disclosure should test the runway thesisHigh impact

The key near-term check is whether the upcoming Q1 disclosure supports management's March statement that cash, cash equivalents, and available-for-sale securities were $143.5 million at December 31, 2025 and provided operational runway through 2028, especially with SAFEGUARD enrollment costs still ahead [#PR-2026-03-09] [#10-K-2026-03-09].

2026-12-31catalystSAFEGUARD enrollment progress remains the main value driverHigh impact

Management said SAB-142 Phase 2b SAFEGUARD enrollment is ongoing, on track to complete by the end of 2026, with topline data expected in 2H 2027; a clean enrollment cadence would help support the lead-program thesis, while slippage would hurt sentiment in a low-coverage biotech name [#PR-2026-03-09] [#10-K-2026-03-09].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-09 • Updated nightlySource: Internal modelMethodology